These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31849313)

  • 1. [Uncontrolled Arterial Hypertension: Kidney, Neurohormonal Imbalance, and Approaches to Antihypertensive Drug Therapy].
    Kuzmin OB; Buchneva NN; Zhezha VV; Serdyuk SV
    Kardiologiia; 2019 Dec; 59(12):64-71. PubMed ID: 31849313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in understanding and managing resistant/refractory hypertension.
    Doumas M; Imprialos KP; Kallistratos MS; Manolis AJ
    F1000Res; 2020; 9():. PubMed ID: 32201574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
    Widimský J
    Vnitr Lek; 2015 Dec; 61(12):1067-71. PubMed ID: 26806502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PURLs: Resistant hypertension? Time to consider this fourth-line drug.
    Kaysin A; Mounsey A
    J Fam Pract; 2016 Apr; 65(4):266-8. PubMed ID: 27262250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016 Oct; 42(7):e108-e109. PubMed ID: 26948046
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistant hypertension: Renal denervation or intensified medical treatment?
    Morganti A; Mancia G
    Eur J Intern Med; 2018 Apr; 50():6-11. PubMed ID: 29287767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistant Hypertension: Time to Consider the Best Fifth Anti-Hypertensive Treatment.
    Pio-Abreu A; Drager LF
    Curr Hypertens Rep; 2018 Jun; 20(8):67. PubMed ID: 29909538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and pharmacologic approach to patients with resistant hypertension.
    Adams M; Bellone JM; Wright BM; Rutecki GW
    Postgrad Med; 2012 Jan; 124(1):74-82. PubMed ID: 22314117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory versus resistant hypertension.
    Siddiqui M; Calhoun DA
    Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):14-19. PubMed ID: 27798457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
    J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.
    de la Sierra A; Armario P; Oliveras A; Banegas JR; Gorostidi M; Vinyoles E; de la Cruz JJ; Segura J; Ruilope LM
    J Hypertens; 2018 Jul; 36(7):1563-1570. PubMed ID: 29601411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial.
    Azizi M; Pereira H; Hamdidouche I; Gosse P; Monge M; Bobrie G; Delsart P; Mounier-Véhier C; Courand PY; Lantelme P; Denolle T; Dourmap-Collas C; Girerd X; Michel Halimi J; Zannad F; Ormezzano O; Vaïsse B; Herpin D; Ribstein J; Chamontin B; Mourad JJ; Ferrari E; Plouin PF; Jullien V; Sapoval M; Chatellier G;
    Circulation; 2016 Sep; 134(12):847-57. PubMed ID: 27576780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels.
    Judd EK; Calhoun DA; Warnock DG
    Semin Nephrol; 2014; 34(5):532-9. PubMed ID: 25416662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone and doxazosin treatment in patients with resistant hypertension.
    Rodilla E; Costa JA; Pérez-Lahiguera F; Baldó E; González C; Pascual JM
    Rev Esp Cardiol; 2009 Feb; 62(2):158-66. PubMed ID: 19232189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endovascular radiofrequency denervation of renal arteries as an innovation method of treatment of refractory arterial hypertension. First experience in Russia].
    Danilov NM; Matchin IuG; Chazova IE
    Angiol Sosud Khir; 2012; 18(1):51-4. PubMed ID: 22836328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.
    Siddiqui M; Dudenbostel T; Calhoun DA
    Can J Cardiol; 2016 May; 32(5):603-6. PubMed ID: 26514749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.